Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 847-854

  Park, So Hyang ^a,b   Gray, William C ^a   Hernandez, Iris ^d   Jacobs, Maria ^a   Ord, Robert A ^c   Sutharalingam, Mohan ^a   Smith, Ruth G ^a   Van Echo, David A ^a   Wu, Suhlan ^b   Conley, Barbara A ^a,b,e  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^c UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^d BALTIMORE VA MEDICAL CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; RETINOIC ACID; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; ECZEMA; FEMALE; HEAD AND NECK CARCINOMA; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXANTHEMA; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HEADACHE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; MOUTH MUCOSA; NEOPLASM STAGING; STOMATITIS; TREATMENT OUTCOME; TRETINOIN;

EID: 12944332005     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics. CA Cancer J. Clin., 49: 8-31, 1999.
2. Million, R. R. Natural history of squamous cell carcinoma. In: R. R. Million and N. J. Cassisi (eds.), Management of Head and Neck Cancer: A Multidisciplinary Approach, pp. 31-33. Philadelphia: Lippincott, 1994.
3. Cooper, J. S., Pajak, T. F., Rubin, P., Tupchong, L., Brady, L. W., Leibel, S. A., Laramore, G. E., Marcial, V. A., Davis, L. W., and Cox, J. D. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int. J. Radiat. Oncol. Biol. Phys., 17: 449-456, 1989.
4. Lippman, S. M., and Hong, W. K. Chemotherapy and chemoprevention. In: E. N. Myers and J. Y. Suen (eds.), Cancer of the Head and Neck, pp. 782-804. Philadelphia: Saunders, 1996.
5. Hong, W. K., Lippman, S. M., Hittelman, W. N., and Lotan, R. Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic. Clin. Cancer Res., 1: 677-686, 1995.
6. Conley, B. A., and Ord, R. A. Current status of retinoids in chemoprevention of oral squamous cell carcinoma: an overview. J. Cranio-Maxillofacial Surg., 24: 339-345, 1996.
7. Chiesa, F., Tradati, N., Marazza, M., Rossi, N., Boracchi, P., Mariani, L., Clerici, M., Formelli, F., Barzan, L., Carrassi, A., Pastorini, A., Camerini, T., Giardini, R., Zurrida, S., Minn, F. L., Costa, A., DePalo, G., and Veronesi, U. Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. Oral Oncol. Eur. J. Cancer, 28B: 97-102, 1992.
8. Anstrom, A., Petterson, U., Krust, A., Chambon, P., and Voorhees, J. J. Retinoic acid and synthetic analogs differentially activate retinoic acid receptor-dependent transcription. Biochem. Biophys. Res. Commun., 173: 339-345, 1990.
9. Sheik, M. S., Shao, Z. M., Li, X. S., Ordonez, J. V., Conley, B. A., Wu, S., Dawson, M. L., Han, Q. X., Chao, W. R., Quick, T., Niles, R. M., and Fontana, J. A. N-(4-Hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human carcinoma. Carcinogenesis (Lond.), 16: 2477-2486, 1995.
10. Muindi, J. R. F., Frankel, S. R., Huselton, C., DeGrazia, F., Garland, W. A., Young, C. W., and Warrell, R. P., Jr. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res., 52: 2138-2142, 1992.
11. Rigas, J. R., Francis, P. A., Muindi, J. R. F., Kris, M. G., Huselton, C., DeGrazia, F., Orazem, J. P., Young, C. W., and Warrell, R. P., Jr. Constitutive variability in pharmacokinetics of the natural retinoid, all-trans retinoic acid, and its modulation by ketoconazole. J. Natl. Cancer Inst., 85: 1921-1926, 1993.
12. Castaigne, S., Chomienne, C., Daniel, M. T., Ballerini, P., Berger, R., Fenaux, P., and Degos, L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia I. Clinical results. Blood, 76: 1704-1709, 1990.
13. Conley, B. A., Egorin, M. J., Sridhara, R., Finley, R., Hemady, R., Wu, S., Tait, N. S., and Van Echo, D. A. Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother. Pharmacol., 39: 291-299, 1997.
14. Lee, J. S., Newman, R. A., Lippman, S. M., Huber, M. H., Minor, T., Raber, M. N., Krakoff, I. H., and Hong, W. K. Phase I evaluation of all-trans retinoic acid in adults with solid tumors. J. Clin. Oncol., 11: 959-966, 1993.
15. Bugge, C. J. L., Rodriguez, L. C., and Vane, F. M., Determination of isotretinoin or etretinate and their major metabolites in human blood by reverse-phase high-performance liquid chromatography. J. Pharmaceut. Biomed. Anal., 3: 269-277, 1985.
16. Meng-er, H., Yu-chen, Y., Shu-rong, C., Jin-ren, C., Jia-Xiang, L., Lin, Z., Long-jiu, G., and Zhen-yi, W. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 72: 567-572, 1988.
17. Windhorst, D. B., and Nigra, T. General clinical toxicology of oral retinoids. J. Am. Acad. Dermatol., 6: 675-682, 1982.
18. Adamson, P. C., Reamon, G., Finkelstein, J. Z., Feusner, J., Berg, S. L., Blaney, S. M., O'Brien, M., Murphy, R. F., and Balis, F. M. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-2a in pediatric patients with refractory cancer. J. Clin. Oncol., 15: 3330-3337, 1997.
19. Benner, S. E., Pajak, T. F., Lippman, S. M., Barley, C., and Hong, W. K. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long term follow-up. J. Natl. Cancer Inst., 86: 140-141, 1994.